Deal-hungry Perrigo elbows aside competitors for Omega Pharma

Emily Wasserman Deal-hungry Perrigo is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company has entered exclusive talks to acquire ...

Chris Viehbacher leaving Sanofi without a U.S.-style windfall

John Carroll For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts ...

New-drug sales boost plus OTC buyout yields $53B forecast for Bayer

Carly Helfand Bayer is already coasting along sales-wise, with some powerhouse new drugs helping it beat analysts' third-quarter forecasts. And those sales will only keep on growing, ...

Big Pharma backs EU antibiotic R&D plan, Pfizer prompts Karo cuts, Advent closes £146M fund

Nick Paul Taylor In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of ...

Daiichi Sankyo’s new a-fib drug heads toward FDA approval and a crowded market

Damian Garde A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving ...

Copaxone, still growing, helps Teva pass Q3 estimates

Carly Helfand Sales of Teva's multiple sclerosis drug, Copaxone, are still growing–at least for now. The Israeli company's top-seller, whose patent is currently the subject ...

A tale of ‘two worlds’ for Novartis respiratory launches in U.S. and EU

Tracy Staton Targeting different markets naturally requires using different marketing strategies. But for Novartis, which is aiming to become a major respiratory player, its approaches ...

Xencor moves on without Amgen, ditching its hopes in arthritis

Damian Garde Xencor has reacquired the rights to an Amgen-optioned antibody, walking away from the Big Biotech and an arthritis indication with hopes of a new path in rare disease. FierceBiotech ...

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

Tracy Staton When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing ...

Scripps cancer spinout Xcovery grabs $20M from a pharma partner in China

John Carroll Chris Liang had already forged a compelling profile in drug development when the newly formed Scripps Florida recruited him as head of chemistry back in 2004. Liang, who ...

GlaxoSmithKline cozies up to Five Prime for respiratory R&D

Damian Garde GlaxoSmithKline, facing widespread scrutiny for its underperforming respiratory business, has expanded its relationship with Five Prime Therapeutics, digging in to discover ...

Yervoy, Sprycel, Eliquis jumps help Bristol-Myers beat Q3 estimates

Carly Helfand The patent cliff may still be taking a toll on Bristol-Myers Squibb, but the company's Q3 sales haul was enough to impress analysts thanks to star performances from ...
Page 1 of 612345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS